About Profectus BioSciences Inc.
Profectus Biosciences is an innovative R&D clinical-stage vaccine company devoted to advancing the treatment and prevention of chronic viral diseases. ProfectusVAX™, the Profectus proprietary vaccine approach combines its plasmid (p) DNA and rVSV (recombinant Vesicular Stomatitis Virus) vector platforms in a unique prime-boost strategy to enhance immune responses to viruses that cause chronic disease. Profectus has a pipeline of proprietary vaccine products to address diseases caused by Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), Human Papilloma Virus (HPV), and Herpes Simplex Virus (HSV) as well as for Malaria. The first of three proof-of-concept clinical trials with the prime/boost HIV vaccine candidate is planned for H1 of 2010, followed by a therapeutic HCV vaccine.
The Profectus portfolio has secured over $100M in non-dilutive funding of its programs from multiple sources including the National Institutes of Health (NIH) and $19M in private equity financing, including Cross Atlantic Capital Partners (XACP). Profectus deploys these financial resources in support of its proprietary prime-boost vaccines for multiple indications. In addition, the Company is funding its early research small molecule program for potential partners. For more information, please visit: http://www.profectusbiosciences.com.
Copyright©2010 Vocus, Inc.
All rights reserved